 Connection
Edward Havranek to Creatinine
This is a "connection" page, showing publications Edward Havranek has written about Creatinine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.112 |
|
|
|
-
Smith GL, Shlipak MG, Havranek EP, Foody JM, Masoudi FA, Rathore SS, Krumholz HM. Serum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular disease. Arch Intern Med. 2006 May 22; 166(10):1134-42.
Score: 0.060
-
Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation. 2005 Jul 05; 112(1):39-47.
Score: 0.014
-
Smith GL, Shlipak MG, Havranek EP, Masoudi FA, McClellan WM, Foody JM, Rathore SS, Krumholz HM. Race and renal impairment in heart failure: mortality in blacks versus whites. Circulation. 2005 Mar 15; 111(10):1270-7.
Score: 0.014
-
Masoudi FA, Rathore SS, Wang Y, Havranek EP, Curtis JP, Foody JM, Krumholz HM. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004 Aug 10; 110(6):724-31.
Score: 0.013
-
Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002 Mar 19; 105(11):1348-53.
Score: 0.011
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|